Results 41 to 50 of about 160,832 (337)

SLC39A1 contributes to gemcitabine resistance of pancreatic ductal adenocarcinoma by activating AMPK signaling

Bangladesh Journal of Pharmacology
Gemcitabine is a common first-line chemotherapy agent, but gemcitabine resistance is a clinical challenge for pancreatic ductal adenocarcinoma patients.
Hao Yu, Xiaoping Mei, Xueming Zhang, Neng Qian, Qingjiang Yu, Hongkun Zhou   +5 more
doaj   +1 more source

microRNA‐99a‐5p induces cellular senescence in gemcitabine‐resistant bladder cancer by targeting SMARCD1

Molecular Oncology, 2022
Patients with advanced bladder cancer are generally treated with a combination of chemotherapeutics, including gemcitabine, but the effect is limited due to acquisition of drug resistance. Thus, in this study, we investigated the mechanism of gemcitabine
Motoki Tamai, Shuichi Tatarano, Shunsuke Okamura, Wataru Fukumoto, Issei Kawakami, Yoichi Osako, Takashi Sakaguchi, Satoshi Sugita, Masaya Yonemori, Yasutoshi Yamada, Masayuki Nakagawa, Hideki Enokida, Hirofumi Yoshino   +12 more
doaj   +1 more source

Challenges of drug resistance in the management of pancreatic cancer [PDF]

, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Akada, Allison, Almoguera, Andreetta, Arai, Arlt, Arteaga, Arumugam, Asano, Bachem, Baldwin, Banerjee, Bartsch, Bergers, Best, Bold, Bondar, Buck, Burris, Chakravarti, Chakravarti, Choi, Cunningham, Cunningham, Dancer, Dong, Duxbury, Duxbury, Duxbury, Duxbury, Engelman, Feldmann, Ferrero, Galmarini, Geyer, Giovannetti, Goan, Greer, Hagmann, Hahn, Henke, Hruban, Humeniuk, Ischenko, Ishikawa, Itoi, Jansen, Karapetis, Kindler, Kong, Koopman, Kulik, Lei, Lemoine, Liau, Liau, Longley, Mackey, Mackey, Mackey, Mahon, Mamaghani, Marechal, Marmor, Martin Clynes, Mata, Maxwell, Mendelsohn, Meropol, Miwa, Moertel, Molina-Arcas, Moore, Morgillo, Moriyama, Muerkoster, Muerkoster, Nakahira, Nakajima, Nakano, Naomi Walsh, Nishimura, Oguri, Okamoto, Okumura, Olive, O’Driscoll, Pao, Park, Park, Peters, Plunkett, Ray McDermott, Ritzel, Rizwan Sheikh, Robert O’Connor, Ruggeri, Safran, Saito, Sakamoto, Schuller, Sebastiani, Shah, Shi, Simon, Spratlin, Takao, Takebayashi, Treat, Tsukamoto, Tzeng, Vaishampayan, Van Cutsem, van der Wilt, Wang, Wang, Wang, Xiong, Yamasaki, Yokoi   +119 more
core   +1 more source

Gemcitabine promotes autophagy and lysosomal function through ERK- and TFEB-dependent mechanisms

Cell Death Discovery, 2023
Gemcitabine is a first-line treatment agent for pancreatic ductal adenocarcinoma (PDAC). Contributing to its cytotoxicity, this chemotherapeutic agent is primarily a DNA replication inhibitor that also induces DNA damage. However, its therapeutic effects
Benoît Marchand, Marc-Antoine Poulin, Christine Lawson, Lee-Hwa Tai, Steve Jean, Marie-Josée Boucher   +5 more
doaj   +1 more source

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study [PDF]

, 2018
Purpose: Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and 6, has demonstrated preclinical activity in non–small cell lung cancer (NSCLC).
Beckmann, Richard, Garrido, Pilar, Goldman, Jonathan W., Gutierrez, Martin, Hossain, Anwar, Jalal, Shadia, John, William J., Johnston, Erica L., Kambhampati, Siva Rama Prasad, Kelly, Karen, Kim, Edward S., Mahadevan, Daruka, Paz-Ares, Luis G., Provencio, Mariano, Schaefer, Eric, Shaheen, Monte, Turner, P. Kellie   +16 more
core   +1 more source

PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy [PDF]

, 2017
Pancreatic ductal adenocarcinoma (PDAC) is considered a non‐immunogenic tumor, and immune checkpoint inhibitor monotherapy lacks efficacy in this disease. Radiotherapy (RT) can stimulate the immune system.
Azad, Abul, D'Costa, Zenobia, Diana, Angela, Dushek, Omer, Fokas, Emmanouil, Jones, Keaton, Kruger, Philipp, Liu, Stanley, McKenna, W. Gillies, Muschel, Ruth J., Sansom, Owen J., Yin Lim, Su   +11 more
core   +1 more source

Reconfigurable Nucleic Acid Nanoparticles with Therapeutic RNAi Responses to Intracellular Disease Markers

Advanced Functional Materials, EarlyView.
Many known diseases arise from dysregulated gene expression, and differentially expressed genes can serve as biomarkers to distinguish diseased cells from healthy tissues. In this study, reconfigurable nucleic acid nanoparticles (recNANPs) are introduced that can detect overexpressed cancer biomarkers and subsequently release RNAi inducers to silence ...
Yelixza I. Avila, Anh Ha, Morgan R. Chandler, Nathalia Leal Santos, Taejin Kim, Hannah S. Newton, Marina A. Dobrovolskaia, Kirill A. Afonin   +7 more
wiley   +1 more source

Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells [PDF]

, 2015
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and incurable disease. Poor prognosis is due to multiple reasons, including acquisition of resistance to gemcitabine, the first-line chemotherapeutic approach.
Bielli, P, Calabretta, S, Capurso, G, DELLE FAVE, Gianfranco, Fendrich, V, Passacantilli, I, Pilozzi, Emanuela, Sette, C.   +7 more
core   +2 more sources

Magnetic Bioprinting and Actuation of Stretchable Muscle Tissue

Advanced Healthcare Materials, EarlyView.
Human and murine myoblasts labeled with iron oxide nanoparticles are magnetically bioprinted into wrench‐shaped tissues, which are then anchored between two magnetic needles. Mechanical stretching of these tissues enhances both their maturation and functional performance. Abstract Engineering tissues with precise, long‐lasting shapes and the capability
Noam Demri, Lise Morizur, Simon Dumas, Giacomo Gropplero, Cécile Martinat, Stéphanie Descroix, Claire Wilhelm   +6 more
wiley   +1 more source

Interdependence of Gemcitabine Treatment, Transporter Expression, and Resistance in Human Pancreatic Carcinoma Cells

Neoplasia: An International Journal for Oncology Research, 2010
Gemcitabine is widely used as first-line chemotherapeutic drug in the treatment of pancreatic cancer. Our previous experimental chemotherapy studies have shown that treatment of human pancreatic carcinoma cells with 5-fluorouracil (5-FU) alters the ...
Wolfgang Hagmann, Ralf Jesnowski, Johannes Matthias Löhr   +2 more
doaj   +1 more source